NEOGEN® CHEMICALS LTD.

August 31, 2026

BSE Limited
Department of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001
Scrip Code No: 542665
Debt Segment Code: 977028

National Stock Exchange of India Limited
Listing Department,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051
Company Symbol: NEOGEN

Dear Sir/Madam,

Sub: Disclosure pursuant to regulation 30 (9) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

With reference to the captioned subject, we wish to inform you that the Board of Directors of Neogen Ionics Limited ("**NIL**") – a wholly owned subsidiary of Neogen Chemicals Limited **("the Company**") and the Board of Neogen Morita New Materials Limited ("**NML**")- a wholly owned subsidiary of NIL and a step down wholly owned subsidiary of the Company, had at its meeting held today i.e., Monday, August 31, 2026, inter alia considered and approved the Execution of Business Transfer Agreement ("**BTA"**) between NIL and NML for sale/ transfer of undertaking/ assets as mentioned in detail in the annexure to the BTA by NIL to NML, on a going concern basis, for a lumpsum consideration of Rs. 245 Crore, subject to approval of shareholders of NIL and such regulatory approvals, as may be required and completion of condition precedents as set out in the BTA. Further the necessary approvals were granted by the shareholders of NIL for the said transaction in its meeting held today i.e. August 31, 2026.

The details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time ("**SEBI Circulars**"), with respect to the said BTA is enclosed herewith as **Annexure 1.**

The above information is also being uploaded on the Company's website at https://neogenchem.com/announcements/ > other disclosure pursuant to regulation 30 and at the website of the NSE (www.nseindia.com) and BSE (www.bseindia.com).

Kindly take the above information on your records.

Thanking you,
For Neogen Chemicals Limited

UNNATI RAJESH KANANI
Digitally signed by UNNATI RAJESH KANANI
Date: 2026.08.31 22:44:59 +05'30'

Unnati Kanani
Company Secretary & Compliance Officer
Mem. No: A35131
Place: Thane
Encl.: As above

Annexure 1

Execution of BTA for Sale/ transfer of undertaking/ assets by NIL to NML

<table>
<tr><th></th><th>PARTICULARS</th><th>DETAILS</th></tr>
<tr><td>a)</td><td>the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;</td><td>The amount and percentage of the turnover or revenue or income and net worth contributed by the said undertaking of NIL during the last financial year is as under:
<table>
<tr><th>Particulars</th><th>Rs. in crores</th><th>%</th></tr>
<tr><td>Revenue from operations as per Profit and Loss Statement for the year ended on March 31, 2026</td><td>Nil</td><td>0% of consolidated revenue of the Company and of the NIL</td></tr>
<tr><td>Net worth as per Balance Sheet as at March 31, 2026</td><td>155.52</td><td>19.05% of consolidated net worth of the Company and
57.36% of consolidated net worth of NIL</td></tr>
</table></td></tr>
<tr><td>b)</td><td>date on which the agreement for sale has been entered into;</td><td>The Business Transfer Agreement shall be executed in a weeks' time, between NIL and NML ("BTA").</td></tr>
<tr><td>c)</td><td>the expected date of completion of sale/disposal;</td><td>Likely to be completed on or before March 31, 2027.</td></tr>
<tr><td>d)</td><td>consideration received from such sale/disposal;</td><td>The undertaking is proposed to be transferred to NML as a going concern, subject to necessary approvals and customary completion of condition precedents and in accordance with the BTA.

The value of such consideration including the relevant assets and after deducting the relevant liabilities, aggregates to a net amount of Rs. 245 Crore. The aforesaid consideration shall be received on or before March 31, 2027, as per the terms and conditions set out under the BTA.</td></tr>
<tr><td>e)</td><td>brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;</td><td>Neogen Ionics Limited ("NIL") – is a wholly owned subsidiary of Neogen Chemicals Limited ("the Company") and Neogen Morita New Materials Limited ("NML")- is a wholly owned subsidiary of NIL and a step down wholly owned subsidiary of the Company.

NIL and NML are not a member of promoter and promoter group of the Company.</td></tr>
<tr><td>f)</td><td>whether the transaction would fall within related party transactions?
If yes, whether the same is done at "arm's length";</td><td>Yes, the transaction falls under the category of related party transaction(s) between a wholly owned subsidiary (i.e. NIL) and step-down wholly owned subsidiary (i.e. NML) of the Company (i.e. Neogen Chemicals Limited). The Company is interested in NIL and NML, to the extent of the share capital held by the</td></tr>
</table>

		Company in NIL and NML. The said transaction is exempted under regulation 23 of Listing Regulations and section 188 of the Companies Act, 2013 and the same is done at an arm's length basis.
g)	**whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.**	The said transaction does not form part of any scheme of arrangement. The said transaction will be undertaken pursuant to the BTA executed between NIL and NML. The said undertaking of NIL does constitute an undertaking in terms of Section 180 of the Companies Act, 2013. Therefore, approvals under Section 180 of the Companies Act, 2013 is obtained. Further as the transaction is between a wholly owned subsidiary (i.e. NIL) and a step-down wholly owned subsidiary (i.e. NML) of the Company (i.e. NCL) the approval under regulation 37A of Listing Regulations is not applicable.
	Additional details in case of a slump sale, as applicable for amalgamation/merger are provided as under:	
h)	**name of the entity(ies) forming part of the transaction, details in brief such as, size, turnover etc.;**	The BTA shall be executed between NIL and NML. NIL is an unlisted public limited company incorporated under the laws of India on March 29, 2023, and is a wholly owned subsidiary of the Company, having its registered office at 1002, 10th Floor, Dev Corpora Building, Cadbury Junction, Khopat, Thane (W) – 400601, Maharashtra, India. It has presence in India. NIL is engaged in the business of manufacturing of Chemicals (including but not limited to Specialty Organic and Inorganic Chemicals) comprising of battery materials, electrolyte, electrolyte salts, electrolyte additives and others as specified in detail in Memorandum of Association of NIL. Its authorised capital is 1,00,00,000 Equity Shares of Rs. 10 each amounting to Rs. 10,00,00,000 and paid – up capital is 99,00,000 Equity Shares of Rs. 10 each amounting to Rs. 9,90,00,000. Its Turnover as on March 31, 2026 was Rs. 35.97 crore. NML is an unlisted public limited company incorporated under the laws of India on July 30, 2025, and is a wholly owned subsidiary of NIL and Step-down wholly owned subsidiary of the Company, having its registered office at 1002, 10th Floor, Dev Corpora Building, Cadbury Junction, Khopat, Thane (W) – 400601, Maharashtra, India. It has presence in India. NML is engaged in the business of manufacturing of Chemicals (including but not limited to Specialty Organic and Inorganic Chemicals) comprising of electrolyte salts such as $LiPF_6$, $NaPF_6$ and others, as specified in detail in Memorandum of Association of NML. Its authorised capital is 99,00,000 Equity Shares of Rs. 10 each amounting to Rs. 9,90,00,000 and paid – up capital is 72,00,000 Equity Shares of Rs. 10 each fully paid-up amounting to Rs. 7,20,00,000. Its Turnover as on March 31, 2026, was Nil.

i)	**whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";**	Please refer point no. (f) above
j)	**area of business of the entity(ies);**	Please refer point no. (h) above
k)	**rationale;**	The transfer of the undertaking is part of Neogen's strategic initiative to consolidate its Electrolyte Salt (LiPF6) businesses under NML.
l)	**in case of cash consideration – amount or otherwise share exchange ratio;**	Rs. 245 Crore.
m)	**brief details of change in shareholding pattern (if any) of listed entity.**	Not applicable.

For Neogen Chemicals Limited

UNNATI RAJESH KANANI

Digitally signed by UNNATI RAJESH KANANI
Date: 2026.08.31 22:45:15 +05'30'

____

Unnati Kanani
Company Secretary & Compliance Officer
Mem. No: A35131
Place: Thane